ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography

View Author Information
PET Centre, Centre for Addiction and Mental Health and Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario M5T 1R8, Canada
Cite this: J. Med. Chem. 2005, 48, 12, 4153–4160
Publication Date (Web):May 19, 2005
Copyright © 2005 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    In vivo imaging of dopamine D2 receptors with agonist (as opposed to the more commonly employed antagonist) radiotracers could provide important information on the high-affinity (functional) state of the D2 receptor in illnesses such as schizophrenia, movement disorders, and addictions. We report here the radiosynthesis and evaluation of the potent D2 agonist (+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, (+)-3, labeled with carbon-11, as a potential radiotracer for imaging the high-affinity state of dopamine D2 receptors with positron emission tomography (PET). [11C]-(+)-3 was reliably synthesized in the quantities and at the specific activities and radiochemical purities required for human PET studies. Ex vivo biodistribution studies in rat brain demonstrated that [11C]-(+)-3 crossed the blood−brain barrier readily and had an appropriate regional brain distribution for a radiotracer that maps dopamine D2 receptors. The binding of [11C]-(+)-3 was saturable and demonstrated an excellent signal-to-noise ratio as measured by its striatum-to-cerebellum ratio of 5.6, 60 min postinjection. The binding was highly stereospecific, and blocking and displacement studies were consistent with selective and specific binding to the dopamine D2 receptors. Further, [11C]-(+)-3 showed marked and appropriate sensitivity to both increases and decreases in the levels of endogenous dopamine. Brain radioactive metabolite and physicochemical measurements are in full accord with the desired properties of a neuroreceptor imaging agent for PET. All of the above, coupled with the documented full D2 agonistic properties of (+)-3, strongly indicate that [11C]-(+)-3 is a leading candidate radiotracer for the imaging of the dopamine D2 high-affinity state using PET in human subjects.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


     To whom correspondence should be addressed. Phone:  416 979 4286. Fax:  416 979 4656. E-mail [email protected].

    Supporting Information Available

    Jump To

    Results from elemental analysis. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 200 publications.

    1. Taichiro Touge, Hideki Nara, Michio Kida, Kazuhiko Matsumura, Yoshihito Kayaki. Convincing Catalytic Performance of Oxo-Tethered Ruthenium Complexes for Asymmetric Transfer Hydrogenation of Cyclic α-Halogenated Ketones through Dynamic Kinetic Resolution. Organic Letters 2021, 23 (8) , 3070-3075.
    2. NaYe, John L. Neumeyer, Ross J. Baldessarini, XuechuZhen, and Ao Zhang . Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chemical Reviews 2013, 113 (5) , PR123-PR178.
    3. Christopher J. R. Fookes, Tien Q. Pham, Filomena Mattner, Ivan Greguric, Christian Loc’h, Xiang Liu, Paula Berghofer, Rachael Shepherd, Marie-Claude Gregoire and Andrew Katsifis. Synthesis and Biological Evaluation of Substituted [18F]Imidazo[1,2-a]pyridines and [18F]Pyrazolo[1,5-a]pyrimidines for the Study of the Peripheral Benzodiazepine Receptor Using Positron Emission Tomography. Journal of Medicinal Chemistry 2008, 51 (13) , 3700-3712.
    4. Ao Zhang,, John L. Neumeyer, and, Ross J. Baldessarini. Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents:  Potential Therapeutics for Neurological and Psychiatric Disorders. Chemical Reviews 2007, 107 (1) , 274-302.
    5. Matthäus Willeit, Ulrich Sauerzopf, Nicole Praschak-Rieder, Ana Weidenauer. The relationship between prefrontal cortex gray matter volume and subcortical dopamine release - an addendum. Molecular Psychiatry 2024, 27
    6. Jiaqi Niu, Yan Zhong, Chentao Jin, Peili Cen, Jing Wang, Chunyi Cui, Le Xue, Xingyue Cui, Mei Tian, Hong Zhang. Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease. Neuroscience Bulletin 2024, 4
    7. Keiko Matsunaga, Misato Tonomura, Kohji Abe, Eku Shimosegawa. Effect of scan-time shortening on the 11C-PHNO binding potential to dopamine D3 receptor in humans and test–retest reliability. Annals of Nuclear Medicine 2023, 37 (4) , 227-237.
    8. Jason Bini, Richard E. Carson, Gary W. Cline. Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo. 2023, 61-74.
    9. Francesco Petragnano, Irene Fasciani, Clotilde Mannoury la Cour, Benjamin di Cara, Gabriella Aloisi, Marco Carli, Shivakumar Kolachalam, Mario Rossi, Francesco Marampon, Marco Scarselli, Mark J. Millan, Roberto Maggio. Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging. European Journal of Pharmacology 2022, 925 , 175016.
    10. Eugenii A. Rabiner, Tolga Uz, Ayla Mansur, Terry Brown, Grace Chen, Jingtao Wu, Joy Atienza, Adam J. Schwarz, Wei Yin, Yvonne Lewis, Graham E. Searle, Jeremy M. T. J. Dennison, Jan Passchier, Roger N. Gunn, Johannes Tauscher. Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET. Neuropsychopharmacology 2022, 47 (7) , 1405-1412.
    11. Linyang Ji, Yi Fang, Jie Tang, Chunyi Liu, Caiyun Huang, Qianyue Hu, Qingming Li, Zhengping Chen. Synthesis and biological evaluation of 18F-labelled dopamine D3 receptor selective ligands. Bioorganic & Medicinal Chemistry Letters 2022, 62 , 128630.
    12. Béla Kiss, Balázs Krámos, István Laszlovszky. Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo. Frontiers in Psychiatry 2022, 13
    13. Lucero Aceves-Serrano, Jason L. Neva, Doris J. Doudet. Insight Into the Effects of Clinical Repetitive Transcranial Magnetic Stimulation on the Brain From Positron Emission Tomography and Magnetic Resonance Imaging Studies: A Narrative Review. Frontiers in Neuroscience 2022, 16
    14. Katina C. Calakos, Aleksandra Rusowicz, Brian Pittman, Jean-Dominique Gallezot, Marc N. Potenza, Kelly P. Cosgrove, David Matuskey. Relationships between dopamine D2/3 receptor availability and social-environmental factors in humans. Neuroscience Letters 2022, 771 , 136463.
    15. Sheida Koohsari, Yanghong Yang, David Matuskey. D3 Receptors and PET Imaging. 2022, 251-275.
    16. C.S. Bal, Dhritiman Chakraborthy. Gamma camera imaging in psychiatric disorders. 2022, 18-36.
    17. Krishna Kanta Ghosh, Parasuraman Padmanabhan, Chang-Tong Yang, David Chee Eng Ng, Mathangi Palanivel, Sachin Mishra, Christer Halldin, Balázs Gulyás. Positron emission tomographic imaging in drug discovery. Drug Discovery Today 2022, 27 (1) , 280-291.
    18. Heinz Grunze, Réka Csehi, Christoph Born, Ágota Barabássy. Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System. Frontiers in Psychiatry 2021, 12
    19. Patricia Di Ciano, Harriet de Wit, Esmaeil Mansouri, Sylvain Houle, Isabelle Boileau, Bernard Le Foll. The influence of conditioned stimuli on [11C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence. Scientific Reports 2021, 11 (1)
    20. Chidera C. Chukwueke, Christina N. Nona, Matthew D. McPhee, Esmaeil Mansouri, Dafna S. Rubin-Kahana, Diana Martinez, Isabelle Boileau, Christian S. Hendershot, Bernard Le Foll. Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study. Neuropsychopharmacology 2021, 46 (12) , 2112-2120.
    21. Ragy R. Girgis, Mark Slifstein, Gary Brucato, Lawrence S. Kegeles, Tiziano Colibazzi, Jeffrey A. Lieberman, Anissa Abi-Dargham. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Molecular Psychiatry 2021, 26 (6) , 2504-2513.
    22. Fernando Caravaggio, Natasha Porco, Julia Kim, Edgardo Torres‐Carmona, Eric Brown, Yusuke Iwata, Shinichiro Nakajima, Philip Gerretsen, Gary Remington, Ariel Graff‐Guerrero. Measuring amphetamine‐induced dopamine release in humans: A comparative meta‐analysis of [ 11 C]‐raclopride and [ 11 C]‐(+)‐PHNO studies. Synapse 2021, 75 (5)
    23. Chukwuma U. Ntephe, Arsime Demjaha. Dopamine and Response to Antipsychotic Medication. 2021, 481-524.
    24. O. Eriksson, B. Långström, G. Antoni. News ways of understanding the complex biology of diabetes using PET. Nuclear Medicine and Biology 2021, 92 , 65-71.
    25. Patrick D. Worhunsky, Gustavo A. Angarita, Zu Wei Zhai, David Matuskey, Jean-Dominique Gallezot, Robert T. Malison, Richard E. Carson, Marc N. Potenza. Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder. Neuropsychopharmacology 2021, 46 (2) , 316-324.
    26. Béla Kiss, István Laszlovszky, Balázs Krámos, András Visegrády, Amrita Bobok, György Lévay, Balázs Lendvai, Viktor Román. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders. Biomolecules 2021, 11 (1) , 104.
    27. Arkadiusz Komorowski, Ana Weidenauer, Matej Murgaš, Ulrich Sauerzopf, Wolfgang Wadsak, Markus Mitterhauser, Martin Bauer, Marcus Hacker, Nicole Praschak-Rieder, Siegfried Kasper, Rupert Lanzenberger, Matthäus Willeit. Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. NeuroImage 2020, 223 , 117270.
    28. Ana Weidenauer, Martin Bauer, Ulrich Sauerzopf, Lucie Bartova, Lukas Nics, Sarah Pfaff, Cecile Philippe, Neydher Berroterán-Infante, Verena Pichler, Bernhard M. Meyer, Ulrich Rabl, Patrick Sezen, Paul Cumming, Thomas Stimpfl, Harald H. Sitte, Rupert Lanzenberger, Nilufar Mossaheb, Alexander Zimprich, Pablo Rusjan, Georg Dorffner, Markus Mitterhauser, Marcus Hacker, Lukas Pezawas, Siegfried Kasper, Wolfgang Wadsak, Nicole Praschak-Rieder, Matthäus Willeit. On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry 2020, 10 (1)
    29. Kelly Smart, Jean-Dominique Gallezot, Nabeel Nabulsi, David Labaree, Ming-Qiang Zheng, Yiyun Huang, Richard E. Carson, Ansel T. Hillmer, Patrick D. Worhunsky. Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. NeuroImage 2020, 214 , 116762.
    30. Puneet K. Sharma, Lisa Wells, Gaia Rizzo, Joanna L. Elson, Jan Passchier, Eugenii A. Rabiner, Roger N. Gunn, David T. Dexter, Ilse S. Pienaar. DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. Neurotherapeutics 2020, 17 (3) , 1120-1141.
    31. Kristina Herfert, Julia G. Mannheim, Laura Kuebler, Sabina Marciano, Mario Amend, Christoph Parl, Hanna Napieczynska, Florian M. Maier, Salvador Castaneda Vega, Bernd J. Pichler. Quantitative Rodent Brain Receptor Imaging. Molecular Imaging and Biology 2020, 22 (2) , 223-244.
    32. Esmaeil Mansouri, José N. Nobrega, Matthew N. Hill, Rachel F. Tyndale, Francis S. Lee, Christian S. Hendershot, Laura M. Best, Patricia Di Ciano, Georgia Balsevich, Mathew E. Sloan, Stephen J. Kish, Junchao Tong, Bernard Le Foll, Isabelle Boileau. D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. Neuropsychopharmacology 2020, 45 (5) , 745-752.
    33. Ragy R. Girgis, Andy Forbes, Anissa Abi-Dargham, Mark Slifstein. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology 2020, 45 (5) , 786-792.
    34. Fernando Caravaggio, Patrick Worhunsky, Ariel Graff‐Guerrero, David Matuskey. Further in vivo characterization of [ 11 C]‐(+)‐PHNO uptake into a retina‐like region of interest in humans. Synapse 2020, 74 (3)
    35. Mark Slifstein, Anissa Abi-Dargham, Ragy R Girgis, Raymond F Suckow, Thomas B Cooper, Chaitanya R Divgi, Pierre Sokoloff, Ludovic Leriche, Patrick Carberry, Shunichi Oya, Simon K Joseph, Marlène Guiraud, Agnès Montagne, Valérie Brunner, Florence Gaudoux, Françoise Tonner. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO. Psychopharmacology 2020, 237 (2) , 519-527.
    36. Matthieu Colom, Benjamin Vidal, Luc Zimmer. Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?. Frontiers in Molecular Neuroscience 2019, 12
    37. Sarah Pfaff, Cécile Philippe, Lukas Nics, Neydher Berroterán-Infante, Katharina Pallitsch, Christina Rami-Mark, Ana Weidenauer, Ulrich Sauerzopf, Matthäus Willeit, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak, Verena Pichler. Toward the Optimization of (+)-[ 11 C]PHNO Synthesis: Time Reduction and Process Validation. Contrast Media & Molecular Imaging 2019, 2019 , 1-13.
    38. Mikaeel Valli, Sang Soo Cho, Mario Masellis, Robert Chen, Pablo Rusjan, Jinhee Kim, Yuko Koshimori, Alexander Mihaescu, Antonio P. Strafella. DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum. Molecular Neurobiology 2019, 56 (9) , 6512-6520.
    39. Patricia Di Ciano, Esmaeil Mansouri, Junchao Tong, Alan A. Wilson, Sylvain Houle, Isabelle Boileau, Thierry Duvauchelle, Philippe Robert, Jean Charles Schwartz, Bernard Le Foll. Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans. Neuropsychopharmacology 2019, 44 (7) , 1284-1290.
    40. Vladimir Shalgunov, Aren van Waarde, Jan Booij, Martin C. Michel, Rudi A. J. O. Dierckx, Philip H. Elsinga. Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. Medicinal Research Reviews 2019, 39 (3) , 1014-1052.
    41. Nasrin Abbasi Gharibkandi, Seyed Jalal Hosseinimehr. Radiotracers for imaging of Parkinson's disease. European Journal of Medicinal Chemistry 2019, 166 , 75-89.
    42. Yuko Koshimori, Antonio P. Strafella, Mikaeel Valli, Vivek Sharma, Sang-soo Cho, Sylvain Houle, Michael H. Thaut. Motor Synchronization to Rhythmic Auditory Stimulation (RAS) Attenuates Dopaminergic Responses in Ventral Striatum in Young Healthy Adults: [11C]-(+)-PHNO PET Study. Frontiers in Neuroscience 2019, 13
    43. Verena Pichler, Neydher Berroterán-Infante, Marius Ozenil, Sarah Pfaff, Cécile Philippe, Wolfgang Wadsak. The Radiopharmaceutical Chemistry of Carbon-11: Tracers and Applications. 2019, 221-236.
    44. Jeih-San Liow, Cheryl Morse, Shuiyu Lu, Michael Frankland, George Tye, Sami Zoghbi, Robert Gladding, Anver Shaik, Robert Innis, Amy Newman, Victor Pike. [O-methyl-11C]N-(4-(4-(3-Chloro-2-methoxyphenyl)-piperazin-1-yl)butyl)-1H-indole-2-carboxamide ([11C]BAK4-51) Is an Efflux Transporter Substrate and Ineffective for PET Imaging of Brain D3 Receptors in Rodents and Monkey. Molecules 2018, 23 (11) , 2737.
    45. Saima Malik, Mark Jacobs, Sang-Soo Cho, Isabelle Boileau, Daniel Blumberger, Markus Heilig, Alan Wilson, Zafiris J. Daskalakis, Antonio P. Strafella, Abraham Zangen, Bernard Le Foll. Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans. Brain Imaging and Behavior 2018, 12 (5) , 1306-1317.
    46. Fernando Caravaggio, Enzo Scifo, Etienne L. Sibille, Sergio E. Hernandez-Da Mota, Philip Gerretsen, Gary Remington, Ariel Graff-Guerrero. Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Experimental Eye Research 2018, 175 , 32-41.
    47. Adrienne Müller Herde, Silvan Boss, Yingfang He, Roger Schibli, Linjing Mu, Simon Ametamey. Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain. Pharmaceuticals 2018, 11 (3) , 83.
    48. Patricia Di Ciano, Rachel F Tyndale, Esmaeil Mansouri, Christian S Hendershot, Alan A Wilson, Dina Lagzdins, Sylvain Houle, Isabelle Boileau, Bernard Le Foll. Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. International Journal of Neuropsychopharmacology 2018, 21 (6) , 503-512.
    49. Fernando Caravaggio, Jun Ku Chung, Eric Plitman, Isabelle Boileau, Philip Gerretsen, Julia Kim, Yusuke Iwata, Raihaan Patel, M. Mallar Chakravarty, Gary Remington, Ariel Graff‐Guerrero. The relationship between subcortical brain volume and striatal dopamine D 2/3 receptor availability in healthy humans assessed with [ 11 C]‐raclopride and [ 11 C]‐(+)‐PHNO PET. Human Brain Mapping 2017, 38 (11) , 5519-5534.
    50. Patricia Di Ciano, Patrick Mc Cormick, Cristiana Stefan, Ernest Wong, Aaron Kim, Gary Remington, Bernard Le Foll. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. Psychopharmacology 2017, 234 (22) , 3309-3320.
    51. Giulia Boscutti, Mickael Huiban, Jan Passchier. Use of carbon-11 labelled tool compounds in support of drug development. Drug Discovery Today: Technologies 2017, 25 , 3-10.
    52. Manabu Kubota, Tomohisa Nagashima, Harumasa Takano, Fumitoshi Kodaka, Hironobu Fujiwara, Keisuke Takahata, Sho Moriguchi, Yasuyuki Kimura, Makoto Higuchi, Yoshiro Okubo, Hidehiko Takahashi, Hiroshi Ito, Tetsuya Suhara. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. International Journal of Neuropsychopharmacology 2017, 20 (11) , 928-935.
    53. Robert H. Mach. Small Molecule Receptor Ligands for PET Studies of the Central Nervous System—Focus on G Protein Coupled Receptors. Seminars in Nuclear Medicine 2017, 47 (5) , 524-535.
    54. Bernard Le Foll, Thulasi Thiruchselvam, Shawna Xiaoyun Lu, Shakira Mohammed, Esmaeil Mansouri, Dina Lagzdins, Shinichiro Nakajima, Alan A. Wilson, Ariel Graff‐Guerrero, Patricia Di Ciano, Isabelle Boileau. Investigating the effects of norepinephrine α1 receptor blockade on dopamine levels: A pilot PET study with [ 11 C]‐(+)‐PHNO in controls. Synapse 2017, 71 (7)
    55. Thulasi Thiruchselvam, Alan A. Wilson, Isabelle Boileau, Bernard Le Foll. A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [ 11 C]-(+)-PHNO. Alcoholism: Clinical and Experimental Research 2017, 41 (6) , 1112-1119.
    56. Fernando Caravaggio, Jun Ku Chung, Philip Gerretsen, Gagan Fervaha, Shinichiro Nakajima, Eric Plitman, Yusuke Iwata, Alan Wilson, Ariel Graff-Guerrero. Exploring the relationship between social attachment and dopamine D 2/3 receptor availability in the brains of healthy humans using [ 11 C]-(+)-PHNO. Social Neuroscience 2017, 12 (2) , 163-173.
    57. Patrick D. Worhunsky, David Matuskey, Jean-Dominique Gallezot, Edward C. Gaiser, Nabeel Nabulsi, Gustavo A. Angarita, Vince D. Calhoun, Robert T. Malison, Marc N. Potenza, Richard E. Carson. Regional and source-based patterns of [ 11 C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D 2 and D 3 receptor availability in cocaine-use disorder. NeuroImage 2017, 148 , 343-351.
    58. S. Eberl, A. Katsifis, M. A. Peyronneau, L. Wen, D. Henderson, C. Loc’h, I. Greguric, J. Verschuer, T. Pham, P. Lam, F. Mattner, A. Mohamed, M. J. Fulham. Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111. European Journal of Nuclear Medicine and Molecular Imaging 2017, 44 (2) , 296-307.
    59. Doris Payer, Belinda Williams, Esmaeil Mansouri, Suzanna Stevanovski, Shinichiro Nakajima, Bernard Le Foll, Stephen Kish, Sylvain Houle, Romina Mizrahi, Susan R. George, Tony P. George, Isabelle Boileau. Corticotropin-releasing hormone and dopamine release in healthy individuals. Psychoneuroendocrinology 2017, 76 , 192-196.
    60. Alice Egerton, Oliver D. Howes, Sylvain Houle, Kwame McKenzie, Lucia R. Valmaggia, Michael R. Bagby, Huai-Hsuan Tseng, Michael A. P. Bloomfield, Miran Kenk, Sagnik Bhattacharyya, Ivonne Suridjan, Chistopher A. Chaddock, Toby T. Winton-Brown, Paul Allen, Pablo Rusjan, Gary Remington, Andreas Meyer-Lindenberg, Philip K. McGuire, Romina Mizrahi. Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. Schizophrenia Bulletin 2017, 71 , sbw181.
    61. Jodi J. Weinstein, Muhammad O. Chohan, Mark Slifstein, Lawrence S. Kegeles, Holly Moore, Anissa Abi-Dargham. Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biological Psychiatry 2017, 81 (1) , 31-42.
    62. Mark Slifstein, Anissa Abi-Dargham. Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. Seminars in Nuclear Medicine 2017, 47 (1) , 54-63.
    63. Ana Weidenauer, Martin Bauer, Ulrich Sauerzopf, Lucie Bartova, Nicole Praschak-Rieder, Harald H. Sitte, Siegfried Kasper, Matthäus Willeit. Making Sense of: Sensitization in Schizophrenia. International Journal of Neuropsychopharmacology 2017, 20 (1) , 1-10.
    64. Ragy R. Girgis, Mark Slifstein, Deepak D’Souza, Yih Lee, Antonia Periclou, Parviz Ghahramani, István Laszlovszky, Suresh Durgam, Nika Adham, Nabeel Nabulsi, Yiyun Huang, Richard E. Carson, Béla Kiss, Margit Kapás, Anissa Abi-Dargham, Ashok Rakhit. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology 2016, 233 (19-20) , 3503-3512.
    65. Peter O. Jenkins, Mitul A. Mehta, David J. Sharp. Catecholamines and cognition after traumatic brain injury. Brain 2016, 139 (9) , 2345-2371.
    66. Benjamin B. Tournier, Stergios Tsartsalis, Andrea Dimiziani, Philippe Millet, Nathalie Ginovart. Time-dependent effects of repeated THC treatment on dopamine D2/3 receptor-mediated signalling in midbrain and striatum. Behavioural Brain Research 2016, 311 , 322-329.
    67. Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, Enric I. Canela, Vicent Casadó. Targeting the dopamine D3 receptor: an overview of drug design strategies. Expert Opinion on Drug Discovery 2016, 11 (7) , 641-664.
    68. Patricia Di Ciano, Mihail Guranda, Dina Lagzdins, Rachel F Tyndale, Islam Gamaleddin, Peter Selby, Isabelle Boileau, Bernard Le Foll. Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study. Neuropsychopharmacology 2016, 41 (6) , 1513-1520.
    69. Antoine Leuzy, Eduardo Rigon Zimmer, Jonathan Dubois, Jens Pruessner, Cory Cooperman, Jean-Paul Soucy, Alexey Kostikov, Esther Schirmaccher, René Désautels, Serge Gauthier, Pedro Rosa-Neto. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. Brain Structure and Function 2016, 221 (3) , 1387-1402.
    70. David Matuskey, Patrick Worhunksy, Elizabeth Correa, Brian Pittman, Jean-Dominique Gallezot, Nabeel Nabulsi, Jim Ropchan, Venkatesh Sreeram, Rohit Gudepu, Edward Gaiser, Kelly Cosgrove, Yu-Shin Ding, Marc N. Potenza, Yiyun Huang, Robert T. Malison, Richard E. Carson. Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. NeuroImage 2016, 130 , 241-247.
    71. Doris E. Payer, Mark Guttman, Stephen J. Kish, Junchao Tong, John R. Adams, Pablo Rusjan, Sylvain Houle, Yoshiaki Furukawa, Alan A. Wilson, Isabelle Boileau. D 3 dopamine receptor-preferring [ 11 C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology 2016, 86 (3) , 224-230.
    72. Matthäus Willeit, Ana Popovic, Lucie Bartova, Ulrich Sauerzopf, Martin Bauer, Nicole Praschak-Rieder. In Vivo Imaging of Dopamine Metabolism and Dopamine Transporter Function in the Human Brain. 2016, 203-220.
    73. Bernard Le Foll, Doris Payer, Patricia Di Ciano, Mihail Guranda, Shinichiro Nakajima, Junchao Tong, Esmaeil Mansouri, Alan A Wilson, Sylvain Houle, Jeff H Meyer, Ariel Graff-Guerrero, Isabelle Boileau. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology 2016, 41 (2) , 529-537.
    74. Benjamin H. Rotstein, Steven H. Liang, Michael S. Placzek, Jacob M. Hooker, Antony D. Gee, Frédéric Dollé, Alan A. Wilson, Neil Vasdev. 11 CO bonds made easily for positron emission tomography radiopharmaceuticals. Chemical Society Reviews 2016, 45 (17) , 4708-4726.
    75. Edythe D. London, Milky Kohno, Angelica M. Morales, Michael E. Ballard. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Research 2015, 1628 , 174-185.
    76. Miho Ota, Shintaro Ogawa, Koichi Kato, Chiaki Masuda, Hiroshi Kunugi. Striatal and extrastriatal dopamine release in the common marmoset brain measured by positron emission tomography and [18F]fallypride. Neuroscience Research 2015, 101 , 1-5.
    77. Vladimir Shalgunov, Jan-Peter van Wieringen, Henk M. Janssen, P. Michel Fransen, Rudi A.J.O. Dierckx, Martin C. Michel, Jan Booij, Philip H. Elsinga. Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers. EJNMMI Research 2015, 5 (1)
    78. Sjoerd J. Finnema, Mika Scheinin, Mohammed Shahid, Jussi Lehto, Edilio Borroni, Benny Bang-Andersen, Jukka Sallinen, Erik Wong, Lars Farde, Christer Halldin, Sarah Grimwood. Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology 2015, 232 (21-22) , 4129-4157.
    79. Ragy R. Girgis, Xiaoyan Xu, Roberto B. Gil, Elizabeth Hackett, Najate Ojeil, Jeffrey A. Lieberman, Mark Slifstein, Anissa Abi-Dargham. Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO. Schizophrenia Research 2015, 168 (1-2) , 373-376.
    80. Fernando Caravaggio, Carol Borlido, Alan Wilson, Ariel Graff-Guerrero. Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. Clinica Chimica Acta 2015, 449 , 60-62.
    81. Isabelle Boileau, Shinichiro Nakajima, Doris Payer. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [11C]-(+)-PHNO. European Neuropsychopharmacology 2015, 25 (9) , 1410-1420.
    82. Elia Abi‐Jaoude, Barbara Segura, Ignacio Obeso, Sang Soo Cho, Sylvain Houle, Anthony E. Lang, Pablo Rusjan, Paul Sandor, Antonio P. Strafella. Similar striatal D2/D3 dopamine receptor availability in adults with T ourette syndrome compared with healthy controls: A [ 11 C]‐(+)‐PHNO and [ 11 C]raclopride positron emission tomography imaging study. Human Brain Mapping 2015, 36 (7) , 2592-2601.
    83. Amelie L. Bartuschat, Tamara Schellhorn, Harald Hübner, Peter Gmeiner, Markus R. Heinrich. Fluoro-substituted phenylazocarboxamides: Dopaminergic behavior and N-arylating properties for irreversible binding. Bioorganic & Medicinal Chemistry 2015, 23 (14) , 3938-3947.
    84. Eduardo R Zimmer, Maxime J Parent, Antoine Leuzy, Antonio Aliaga, Arturo Aliaga, Luc Moquin, Esther S Schirrmacher, Jean-Paul Soucy, Ivan Skelin, Alain Gratton, Serge Gauthier, Pedro Rosa-Neto. Imaging in Vivo Glutamate Fluctuations with [ 11 C]ABP688: A GLT-1 Challenge with Ceftriaxone. Journal of Cerebral Blood Flow & Metabolism 2015, 35 (7) , 1169-1174.
    85. Christophe Plisson, Joaquim Ramada‐Magalhaes, Jan Passchier. Synthesis of Carbon‐11 Labeled (+)‐4‐Propyl‐3,4,4a,5,6,10b‐Hexahydro‐2 H ‐Naphtho[1,2‐ B ][1,4]Oxazin‐9‐Ol ([ 11 C]‐(+)‐PHNO). 2015, 81-92.
    86. F. Caravaggio, C. Borlido, M. Hahn, Z. Feng, G. Fervaha, P. Gerretsen, S. Nakajima, E. Plitman, J. K. Chung, Y. Iwata, A. Wilson, G. Remington, A. Graff-Guerrero. Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. International Journal of Neuropsychopharmacology 2015, 18 (7) , pyv014-pyv014.
    87. Kelly P. Cosgrove, Maria G. Veldhuizen, Christine M. Sandiego, Evan D. Morris, Dana M. Small. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Synapse 2015, 69 (4) , 195-202.
    88. Miho Ota, Shintaro Ogawa, Koichi Kato, Chisato Wakabayashi, Hiroshi Kunugi. Methamphetamine-sensitized rats show augmented dopamine release to methylphenidate stimulation: A positron emission tomography using [18F]fallypride. Psychiatry Research: Neuroimaging 2015, 232 (1) , 92-97.
    89. Paul W Czoty, Michael A Nader. Effects of Oral and Intravenous Administration of Buspirone on Food–Cocaine Choice in Socially Housed Male Cynomolgus Monkeys. Neuropsychopharmacology 2015, 40 (5) , 1072-1083.
    90. Doris E. Payer, Mark Guttman, Stephen J. Kish, Junchao Tong, Antonio Strafella, Martin Zack, John R. Adams, Pablo Rusjan, Sylvain Houle, Yoshiaki Furukawa, Alan A. Wilson, Isabelle Boileau. [ 11 C]‐(+)‐PHNO PET imaging of dopamine D 2/3 receptors in Parkinson's disease with impulse control disorders. Movement Disorders 2015, 30 (2) , 160-166.
    91. P.N. McCormick, P.J. Fletcher, V.S. Wilson, J.D.C. Browne, J.N. Nobrega, G.J. Remington. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer. Neuropharmacology 2015, 89 , 225-231.
    92. Sang Soo Cho, Yuko Koshimori, Kelly Aminian, Ignacio Obeso, Pablo Rusjan, Anthony E Lang, Zafiris J Daskalakis, Sylvain Houle, Antonio P Strafella. Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. Neuropsychopharmacology 2015, 40 (3) , 546-553.
    93. James Nairne, Peter B. Iveson, Andreas Meijer. Imaging in Drug Development. 2015, 231-280.
    94. Fernando Caravaggio, Sofia Raitsin, Philip Gerretsen, Shinichiro Nakajima, Alan Wilson, Ariel Graff-Guerrero. Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index. Biological Psychiatry 2015, 77 (2) , 196-202.
    95. Steven H. Liang, Neil Vasdev. Total Radiosynthesis: Thinking Outside ‘the Box'. Australian Journal of Chemistry 2015, 68 (9) , 1319.
    96. Vladimir Shalgunov, Jan-Peter van Wieringen, Henk M. Janssen, P. Michel Fransen, Rudi A.J.O. Dierckx, Martin C. Michel, Jan Booij, Philip H. Elsinga. Synthesis and Evaluation in Rats of the Dopamine D 2/3 Receptor Agonist 18 F-AMC20 as a Potential Radioligand for PET. Journal of Nuclear Medicine 2015, 56 (1) , 133-139.
    97. Flavia Niccolini, Paul Su, Marios Politis. Dopamine receptor mapping with PET imaging in Parkinson’s disease. Journal of Neurology 2014, 261 (12) , 2251-2263.
    98. Natascha Nebel, Simone Maschauer, Amelie L. Bartuschat, Stefanie K. Fehler, Harald Hübner, Peter Gmeiner, Torsten Kuwert, Markus R. Heinrich, Olaf Prante, Carsten Hocke. Synthesis and evaluation of fluoro substituted pyridinylcarboxamides and their phenylazo analogues for potential dopamine D3 receptor PET imaging. Bioorganic & Medicinal Chemistry Letters 2014, 24 (23) , 5399-5403.
    99. Michael Honer, Luca Gobbi, Laurent Martarello, Robert A. Comley. Radioligand development for molecular imaging of the central nervous system with positron emission tomography. Drug Discovery Today 2014, 19 (12) , 1936-1944.
    100. I Boileau, D Payer, B Chugani, D S S Lobo, S Houle, A A Wilson, J Warsh, S J Kish, M Zack. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [11C]-(+)-PHNO. Molecular Psychiatry 2014, 19 (12) , 1305-1313.
    Load all citations

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect